Custom Mots-C CAS: 1627580-64-6 Pricelist, Service
Product Description
MOTS-c is a short peptide composed of 16 amino acids, and its encoding gene is located on mitochondrial DNA. This discovery challenges the conventional wisdom that mitochondrial DNA only encodes respiratory chain-related proteins.
Main function: The core function of MOTS-c is as a regulator of cellular metabolism, particularly in glucose metabolism and insulin sensitivity. It mimics some of the effects of exercise and is therefore also known as a "motor-mimicking peptide".
Mechanism of action: It primarily functions by activating the AMPK pathway, a key energy sensor within cells. This promotes glucose uptake by cells, improves insulin sensitivity, and influences fatty acid metabolism.
Therapeutic Areas
Based on its powerful metabolic regulation capabilities, research on MOTS-c mainly focuses on the following therapeutic areas:
Metabolic Diseases
- Type 2 diabetes: Core research focus. Significantly improves insulin resistance, lowers blood sugar, and has potential as a novel antidiabetic drug.
- Obesity: Promotes energy expenditure, reduces fat accumulation, and induces conversion of white fat into brown fat-like fat (thermogenesis) to assist weight control.
Aging & Related Diseases
- Anti-aging / Extending healthy lifespan: Improves age-related metabolic decline, enhances cellular stress resistance, and shows potential to extend lifespan in animal studies.
- Sarcopenia: Combats age or disease-related muscle loss by improving metabolism and muscle health.
- Neurodegenerative diseases: Preliminary findings suggest protective effects against conditions like Alzheimer's by boosting brain cell energy metabolism and reducing oxidative stress.
Athletic Performance
As a "sports simulator," MOTS-c is being explored for its ability to enhance physical fitness, improve exercise endurance, and accelerate post-exercise recovery.
Other Potential Areas
Shows promising potential in cardiovascular protection, non-alcoholic fatty liver disease (NAFLD), and other conditions closely tied to metabolic disorders.
Outlook & Development
MOTS-c has a promising future, but it remains in the critical transition phase from basic research to clinical application.
Opportunities Prospects
- Novel Target of Action: As the first extensively studied mitochondrial-derived peptide, it opens a brand-new path for drug development with huge market potential.
- Targeting Underlying Mechanisms: Directly addresses the core root of aging and metabolic diseases—cellular energy imbalance—offering multi-faceted benefits.
- "Sports Pills" Concept: Provides therapeutic benefits that mimic exercise for elderly or mobility-impaired individuals, fulfilling a clear market demand.
Challenges Current Status
- R&D Phase: Most data comes from preclinical cell/animal studies; advancing to human clinical trials is the primary challenge.
- Administration Route: As a peptide, it degrades easily. Issues regarding low oral bioavailability and injection-dependent administration must be resolved.
- Long-term Safety & Dosage: Human long-term efficacy, optimal dosing, and side-effect profiles require further investigation.
- Industrialization & Regulation: Large-scale high-quality synthesis and approval from regulatory agencies (FDA/NMPA) are essential for commercial success.
Conclusion
In summary, MOTS-c is a revolutionary biological discovery representing a crucial future direction in metabolic disease therapy and anti-aging research. While its scientific value is well-established, its commercial and clinical success will depend on translational research progress in the coming years as it aims to transition from the laboratory to the medical market.
Frequently Asked Questions (FAQ)
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA. It acts as a primary regulator of cellular energy metabolism and insulin sensitivity.
MOTS-c stimulates cellular responses similar to physical exercise by activating the AMPK pathway, enhancing glucose uptake, increasing insulin sensitivity, and promoting fat burning.
Key research areas include Type 2 diabetes, obesity, sarcopenia, neurodegenerative conditions (like Alzheimer's disease), cardiovascular protection, and anti-aging lifespan extension.
It mainly works by activating AMP-activated protein kinase (AMPK), which acts as the cell's master energy sensor to control glucose utilization and fatty acid breakdown.
Major challenges include moving from preclinical animal studies to human clinical trials, resolving low oral bioavailability (requiring injection), and establishing optimal dosage safety.
No, MOTS-c is currently in the translational research and preclinical phase and has not yet achieved approval as a commercial pharmaceutical drug.
